Clinical Trial Update: Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) [EARLY_Phase 1]

View source ↗

Summary

An early phase 1 trial evaluated vismodegib in patients with basal cell carcinoma, including recurrent skin cancer. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Skin Cancer

Drugs mentioned

• Vismodegib (Vismodegib)

Snippet

Sponsor: Stanford University | Conditions: Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2017-10-02